Strategies to Improve Management of ADPKD: Navigating Pitfalls and Overcoming Challenges
September 24, 2020
September 24, 2021
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by Medical Education Resources and CMEology.
This activity is supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.
- Physicians — maximum of 1.50 AMA PRA Category 1 Credit(s)™
- Nurses — 1.50 Contact Hours
All other health care professionals completing this course will be issued a statement of participation.
The activity is intended for nephrologists, primary care physicians, and other health care providers who care for patients with ADPKD.
Although the most common inherited renal disorder, autosomal dominant polycystic kidney disease (ADPKD) is often underdiagnosed and undertreated. Nephrologists report that ADPKD is associated with the highest unmet need among renal diseases. Unmet needs for the optimal care of patients with ADPKD include improved management of renal and extrarenal manifestations and recognition of genetic factors. With the advent of disease-modifying therapy for ADPKD, it is important to identify patients most likely to benefit from treatment. Identification of patients at risk for rapid progression of renal decline is crucial for individualizing treatment. Nevertheless, health care providers may not be aware of practical strategies to assess prognosis in patients with ADPKD. Translating evidence from ADPKD research into practice is an important strategy for clinicians striving to improve patient care. The identification of clinical implications and generalization of data from the ADPKD literature can be challenging for busy nephrology health care providers. This activity is designed to provide health care providers with enhanced knowledge and competence in state-of-the-art management of ADPKD including appreciation of strategies for interventions to slow the loss of kidney function.
This activity has been designed to enhance the care of patients with ADPKD. The content is tailored to the needs of each participant based on the responses to multiple-choice questions at the beginning of the activity.
Upon completion of this activity, participants should be better able to:
- Employ measures to improve the recognition and management of renal and nonrenal manifestations of ADPKD
- Discuss the clinical implications of ADPKD genotypic factors and when testing is indicated
- Apply strategies for individualizing ADPKD management through assessment of risk for disease progression
- Interpret results of ADPKD research to identify the implications for current patient care
The learning objectives listed above will vary based on participants’ responses to multiple-choice questions at the beginning of the activity.
Arlene Chapman, MD
Professor of Medicine
Chief, Section of Nephrology
Department of Medicine
Director, Clinical Research Center
Institute for Translational Medicine
Biological Sciences Division
University of Chicago
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and CMEology. MER is accredited by the ACCME to provide continuing medical education for physicians.
Medical Education Resources designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This CE activity provides 1.50 contact hours of continuing nursing education.
Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299.
Disclosures of Conflicts of Interest
Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
Arlene Chapman, MD
- Consulting Fees: Reata Pharmaceuticals, Inc. and Sanofi
- Grants/Research Support: Reata Pharmaceuticals, Inc. and Sanofi
CMEology planners have no relationships to disclose.
MER content reviewers have no relationships to disclose.
Instructions for Participation and Credit
There are no fees for participating in and receiving credit for this activity. During the period TBD through TBD, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each question, and 4) complete the evaluation form.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest.
Hardware and Software Requirements
This site is best viewed with an HTML5 compatible browser. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser.
Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the planners. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.